
    
      This is a phase Ib, randomize, interventional, open-label, multicenter study to provide
      fruquintinib to subjects diagnosed with metastatic colorectal cancer who have failed after
      standard therapy and for whom no therapy alternatives exist.

      The primary endpoint of this study will be safety.
    
  